Christopher Doughty - Jun 13, 2025 Form 3 Insider Report for GLYCOMIMETICS INC (CBIO)

Role: Chief Business Officer
Signature: /s/ Barbara Bispham, as attorney-in-fact for Christopher Doughty
Stock symbol: CBIO
Transactions as of: Jun 13, 2025
Transactions value $: $0
Form type: 3
Date filed: 6/23/2025, 06:29 PM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Doughty Christopher Grant	Chief Business Officer	C/O CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM	/s/ Barbara Bispham, as attorney-in-fact for Christopher Doughty	2025-06-23	0002074223

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CBIO	Ordinary Shares						39.5K	Jun 13, 2025	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CBIO	Stock Option (Right to Buy)							Jun 13, 2025	Ordinary Shares	153K	$6.16	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective as of June 13, 2025 (the "Effective Time"), (i) a wholly-owned subsidiary of GlycoMimetics, Inc. ("GlycoMimetics") merged with and into Crescent Biopharma, Inc. ("Pre-Merger Crescent") with Pre-Merger Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger (the "First Merger"), (ii) immediately thereafter, Pre-Merger Crescent merged with and into a second wholly-owned subsidiary of GlycoMimetics ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Crescent Biopharma Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, GlycoMimetics changed its name to "Crescent Biopharma, Inc." (hereinafter, the "Issuer").
F2	This Form gives effect to the Issuer's completion of a conversion from a corporation organized under the laws of the State of Delaware (the "Delaware Corporation") to an exempted company incorporated under the laws of the Cayman Islands (the "Cayman Company"), effective as of June 16, 2025. In connection therewith, (a) each outstanding share of common stock of the Delaware Corporation was automatically converted into one ordinary share of the Cayman Company; and (b) each outstanding option or right to acquire shares of common stock of the Delaware Corporation continued in existence in the form of and automatically became an option or right to acquire an equal number of ordinary shares of the Cayman Company under the same terms and conditions.
F3	Represents the number of restricted ordinary shares of the Issuer received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Crescent's restricted common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Crescent's restricted common stock held at the Effective Time was exchanged for 0.1445 restricted ordinary shares of the Issuer. These restricted ordinary shares will vest as to 25% on September 28, 2025 and in equal monthly installments for the 36 months thereafter through September 28, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F4	Represents options to purchase the Issuer's ordinary shares received by the Reporting Person in the Merger in exchange for options of Pre-Merger Crescent held by the Reporting Person prior to the Merger. 19,098 of the shares subject to the option are fully vested and the remaining 133,684 will vest in equal monthly installments thereafter through December 11, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney